A Screening Study To Assess The Cognition Status in Healthy Volunteers
MULTI-CENTER COGNITION ASSESSMENT IN HEALTHY SUBJECTS TO COLLECT REFERENCE DATA FOR COMPARISON TO PATIENTS WITH DEPRESSION
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Freiburg, Germany, 79104
-
Mainz, Germany, 55131
-
Mannheim, Germany, 68159
-
Schwerin, Mecklenburg-Vorpommern, Germany, 19053
-
-
-
-
-
Bialystok, Poland, 15-464
-
Choroszcz, Poland, 16-070
-
Tuszyn, Poland, 95-080
-
-
-
-
California
-
San Diego, California, United States, 92102
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
-
-
Illinois
-
Oak Brook, Illinois, United States, 60523
-
-
New York
-
Cedarhurst, New York, United States, 11516
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy volunteers, 18 to 65 years of age, inclusive
- Healthy volunteers with a stable chronic disease that is not associated with cognitive deficits (e.g. asthma) and does not require any treatment known to affect cognition have to be discussed with the medical monitor before enrollment
- A body mass index between 18 to 30 kg/m2 inclusive
- Able to participate and willing to give written informed consent and to comply with the study restrictions
- At least second generation resident in the country of origin
Exclusion Criteria:
- Current or past history of a psychiatric disorder
- Family history of psychiatric disorders
- Suspicion or evidence of regular consumption of drugs of abuse or a positive drug test at the screening visit
- Acute or chronic disorder which is not stable or may affect cognition or needs treatment affecting cognition
- Change of smoking behavior or smoking cessation therapy within 30 days before screening visit
- Positive result on hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) 1 and 2
- Systolic blood pressure greater than 140 or less than 90 mm Hg, and diastolic blood pressure greater than 100 or less than 50 mm Hg
- Resting Pulse Rate greater than 100 or less than 45 beats per minute
- Clinically significant abnormalities in laboratory test results or in ECG assessment at screening visit
- Participation in an investigational drug study within 1 month prior to baseline
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Healthy volunteers
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognitive status of volunteers
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BP28865
- 2013-001261-16 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.